BUY GILD · 1 Year pick · Oct 23, 2026
+2% vs analyst target · new source · 1 agree · 0 dissent
Why BUY: Jefferies lifts Gilead to $185 (Buy) after its $1.275B deal for an oral IL-23 drug; shares are up 30% this year.
⚠ It trades ~2% under its 52-week high, and Oct 29 earnings could reset expectations either way.
GILD was $156.40 when we published the BUY call on Oct 23. It's now $157.19, +0.51% for the BUY side.
Source: Yahoo Finance prices, updated Oct 23, 7:09 AM ET.
The Daily Five's 1 Year call from Oct 23 is BUY GILD at $156.40. Why: Jefferies lifts Gilead to $185 (Buy) after its $1.275B deal for an oral IL-23 drug; shares are up 30% this year. Not financial advice.
GILD was $156.40 when we published the BUY call on Oct 23. It's now $157.19, +0.51% for the BUY side.
Our top-scored value pick for NBA: POR @ SAC is priced under the sportsbooks. The side is in the email.